Markel Group Inc. grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 20.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,400 shares of the medical research company's stock after purchasing an additional 6,000 shares during the quarter. Markel Group Inc.'s holdings in Thermo Fisher Scientific were worth $21,897,000 at the end of the most recent reporting period.
A number of other hedge funds have also bought and sold shares of the stock. Signature Resources Capital Management LLC increased its position in shares of Thermo Fisher Scientific by 318.2% in the second quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company's stock valued at $25,000 after buying an additional 35 shares in the last quarter. New Millennium Group LLC purchased a new stake in shares of Thermo Fisher Scientific in the second quarter valued at approximately $29,000. Stephens Consulting LLC boosted its stake in Thermo Fisher Scientific by 116.0% during the second quarter. Stephens Consulting LLC now owns 54 shares of the medical research company's stock worth $30,000 after buying an additional 29 shares during the last quarter. Headlands Technologies LLC acquired a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at about $32,000. Finally, Bank & Trust Co acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at about $33,000. Institutional investors and hedge funds own 89.23% of the company's stock.
Thermo Fisher Scientific Price Performance
Shares of NYSE TMO traded down $4.15 during trading on Friday, hitting $551.74. The company had a trading volume of 1,620,732 shares, compared to its average volume of 1,461,084. The business's 50-day moving average is $593.95 and its 200 day moving average is $583.63. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The company has a market cap of $211.04 billion, a P/E ratio of 34.59, a PEG ratio of 3.70 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 52 week low of $437.26 and a 52 week high of $627.88.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. During the same quarter last year, the firm earned $5.69 earnings per share. The company's revenue for the quarter was up .2% on a year-over-year basis. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current fiscal year.
Thermo Fisher Scientific Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.28%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio is 9.78%.
Analyst Ratings Changes
Several analysts have recently issued reports on the stock. UBS Group raised shares of Thermo Fisher Scientific to a "strong-buy" rating in a research report on Monday, September 16th. Robert W. Baird cut their target price on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating on the stock in a research note on Thursday, October 24th. Royal Bank of Canada lowered their price target on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an "outperform" rating for the company in a report on Thursday, October 24th. Bank of America boosted their price objective on Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a "buy" rating in a research note on Monday, September 16th. Finally, Barclays dropped their price target on Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating on the stock in a research report on Wednesday, October 23rd. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $649.33.
Get Our Latest Stock Report on TMO
Insider Buying and Selling at Thermo Fisher Scientific
In other news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the completion of the sale, the chief executive officer now owns 121,192 shares of the company's stock, valued at approximately $67,175,513.68. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the transaction, the senior vice president now owns 12,736 shares in the company, valued at approximately $7,134,197.76. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the transaction, the chief executive officer now directly owns 121,192 shares of the company's stock, valued at $67,175,513.68. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,150 shares of company stock valued at $15,676,125. 0.34% of the stock is currently owned by company insiders.
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Articles
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
